At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Nov 3, 2026 at 07:00 ET
Rhythm Pharmaceuticals reported Q3 2026 IMCIVREE revenue of $92.1M, a 29% sequential increase and 80% YoY growth, beating the $84.6M consensus. Net loss per share of $(0.61) was narrower than the consensus estimate of $(0.74). The company also secured a $750M term loan facility and amended its bivamelagon license with LG Chem, reducing the royalty to 1% in exchange for $350M in fixed payments.
- Q3 2026 IMCIVREE net product revenue of $92.1M, up 29% sequentially and 80% YoY from $51.3M
- Revenue beat consensus of $84.6M by 8.9%
- GAAP net loss per share of $(0.61) vs consensus estimate of $(0.74)
- Over 700 patient start forms for IMCIVREE in acquired HO from more than 500 prescribers as of Sep 30, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access